Genexine-Kalbe Indonesia JV To Target Biologic Production
This article was originally published in PharmAsia News
South Korean biotech firm Genexine is to set up its fifth joint venture as part of a global push, this time with Kalbe Farma in Indonesia. The venture, KG Bio, will develop and seek regulatory approvals of Genexine's hyFc technology based protein therapies, and Genexine plans to use the new business to strengthen its ASEAN and international business.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.